{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T10:34:39Z","timestamp":1725964479423},"publisher-location":"Chichester, UK","reference-count":46,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd006007.pub2","type":"reference-entry","created":{"date-parts":[[2007,1,25]],"date-time":"2007-01-25T13:35:23Z","timestamp":1169732123000},"source":"Crossref","is-referenced-by-count":4,"title":["Antifibrinolytic amino acids for acquired coagulation disorders in patients with liver disease"],"prefix":"10.1002","author":[{"given":"Arturo J","family":"Mart\u00ed-Carvajal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Sol\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graciela","family":"Nicita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,1,24]]},"reference":[{"issue":"11","key":"10.1002\/14651858.CD006007.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1111\/j.1572-0241.2000.03299.x","article-title":"Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease","volume":"95","author":"Agarwal","year":"2000","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD006007.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/bmj.328.7438.476","article-title":"Absence of evidence is not evidence of absence","volume":"328","author":"Alderson","year":"2004","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006007.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1055\/s-2002-23205","article-title":"Coagulation disorders in liver disease","volume":"22","author":"Amitrano","year":"2002","journal-title":"Seminars in Liver Disease"},{"issue":"7572","key":"10.1002\/14651858.CD006007.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bmj.38987.492014.94","article-title":"How to formulate research recommendations","volume":"333","author":"Brown","year":"2006","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006007.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2141.2005.05444.x","article-title":"Molecular mechanisms of fibrinolysis","volume":"129","author":"Cesarman-Maus","year":"2005","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD006007.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/bmj.328.7438.475","article-title":"Well informed uncertainties about the effects of treatments","volume":"328","author":"Chalmers","year":"2004","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD006007.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/00062752-200211000-00014","article-title":"Transfusion-sparing hemostatic agents","volume":"9","author":"Chiu","year":"2002","journal-title":"Current Opinion in Hematolology"},{"key":"10.1002\/14651858.CD006007.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1365-2141.1993.tb03345.x","article-title":"Decreased contact factor mediated fibrinolysis in cirrhosis","volume":"85","author":"Cohen","year":"1993","journal-title":"British Journal of Haematolology"},{"key":"10.1002\/14651858.CD006007.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1053\/jhep.2003.50277","article-title":"Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis","volume":"38","author":"Colucci","year":"2003","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD006007.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00062752-199909000-00010","article-title":"Management of bleeding with uremia and liver disease","volume":"6","author":"DeLoughery","year":"1999","journal-title":"Current Opinion in Hematolology"},{"issue":"6","key":"10.1002\/14651858.CD006007.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2165\/00003495-199957060-00017","article-title":"Tranexamic acid: a review of its use in surgery and other indications","volume":"57","author":"Dunn","year":"1999","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD006007.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.thromres.2007.07.008","article-title":"Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency","volume":"121","author":"Ferguson","year":"2008","journal-title":"Thrombosis Research"},{"key":"10.1002\/14651858.CD006007.pub2-BIB13|cit13","unstructured":"Gluud C Nikolova D Klingenberg SL Whitfield K Alexakis N Als-Nielsen B Cochrane Hepato-Biliary Group About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2009"},{"key":"10.1002\/14651858.CD006007.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1365-2036.2006.02730.x","article-title":"The efficacy and safety of epsilon-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis","volume":"23","author":"Gunawan","year":"2006","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006007.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000057299","article-title":"General haemostatic agents-fact or fiction?","volume":"32","author":"Hedner","year":"2002","journal-title":"Pathophysiology of Haemostasis and Thrombosis"},{"issue":"6681","key":"10.1002\/14651858.CD006007.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1136\/bmj.298.6681.1142","article-title":"Effects of fibrinolytic inhibitors on mortality from upper gastrointestinal haemorrhage","volume":"298","author":"Henry","year":"1989","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006007.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0140-6736(93)90284-N","article-title":"Fibrinolysis and upper gastrointestinal bleeding","volume":"341","author":"Henry","year":"1993","journal-title":"The Lancet"},{"issue":"7414","key":"10.1002\/14651858.CD006007.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006007.pub2-BIB19|cit19","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008 Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD006007.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1572-0241.2001.03781.x","article-title":"Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit","volume":"96","author":"Hu","year":"2001","journal-title":"American Journal of Gastroenterology"},{"volume-title":"Code of Federal Regulations & Guidelines","year":"1997","key":"10.1002\/14651858.CD006007.pub2-BIB21|cit21"},{"key":"10.1002\/14651858.CD006007.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","article-title":"Better reporting of harms in randomized trials: an extension of the CONSORT statement","volume":"141","author":"Ioannidis","year":"2004","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD006007.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in metaanalyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD006007.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJM199807233390407","article-title":"Hemostatic drugs","volume":"339","author":"Mannucci","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006007.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352(9128)","author":"Moher","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006007.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1503\/cmaj.1040031","article-title":"Opportunities and challenges for improving the quality of reporting clinical research: CONSORT and beyond","volume":"171","author":"Moher","year":"2004","journal-title":"Canadian Medical Association Journal"},{"key":"10.1002\/14651858.CD006007.pub2-BIB27|cit27","first-page":"466","article-title":"The incidence of consumption coagulopathy in liver cirrhosis","volume":"6","author":"Moreno Abad\u00eda","year":"1989","journal-title":"Anales de Medicina Interna"},{"key":"10.1002\/14651858.CD006007.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/hep.1840180611","article-title":"Activation of the fibrinolytic system in patients with fulminant liver failure","volume":"18","author":"Pernambuco","year":"1993","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD006007.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hep.510310214","article-title":"Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices","volume":"31","author":"Piscaglia","year":"2000","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD006007.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1111\/j.1572-0241.2001.05298.x","article-title":"Liver cirrhosis, ascites, and hyperfibrinolysis","volume":"96","author":"Piscaglia","year":"2001","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD006007.pub2-BIB31|cit31","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2008"},{"key":"10.1002\/14651858.CD006007.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"Royle","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"10.1002\/14651858.CD006007.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"408-12","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006007.pub2-BIB34|cit34","first-page":"73","article-title":"Fibrinolysis as a cause of coagulopathy in patients with chronic diffuse diseases of the liver","volume":"69","author":"Serov","year":"1991","journal-title":"Klinicheskaia Meditsina"},{"key":"10.1002\/14651858.CD006007.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3349\/ymj.1993.34.3.234","article-title":"The fibrinogen degradation products (FgDP) levels in liver disease","volume":"34","author":"Song","year":"1993","journal-title":"Yonsei Medical Journal"},{"key":"10.1002\/14651858.CD006007.pub2-BIB36|cit36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ajh.2830340402","article-title":"Fibrinolysis and fibrinogenolysis in liver disease","volume":"34","author":"Takahashi","year":"1990","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD006007.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0753-3322(93)90084-X","article-title":"The hyperfibrinolytic state of liver cirrhosis: possible pathogenetic role of ascites","volume":"47","author":"Toschi","year":"1993","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10.1002\/14651858.CD006007.pub2-BIB38|cit38","first-page":"153","article-title":"Coagulation disorders in cirrhosis","volume":"59","author":"T\u00e9llez-Avila","year":"2007","journal-title":"Revista de Investigaci\u00f3n Cl\u00ednica"},{"key":"10.1002\/14651858.CD006007.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bpg.2007.10.011","article-title":"Epidemiology of acute upper gastrointestinal bleeding","volume":"22","author":"Leerdam","year":"2008","journal-title":"Best Practice & Research. Clinical Gastroenterology"},{"key":"10.1002\/14651858.CD006007.pub2-BIB40|cit40","first-page":"67","article-title":"Coagulation and fibrinolysis in individuals with advanced liver disease","volume":"15","author":"Thiel","year":"2004","journal-title":"The Turkish Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD006007.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2165\/00003495-198529030-00003","article-title":"Clinical application of inhibitors of fibrinolysis","volume":"29","author":"Verstraete","year":"1985","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD006007.pub2-BIB42|cit42","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/hep.1840150420","article-title":"Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis","volume":"15","author":"Violi","year":"1992","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD006007.pub2-BIB43|cit43","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/hep.1840170115","article-title":"Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. The CALC Group. Coagulation abnormalities in liver cirrhosis","volume":"17","author":"Violi","year":"1993","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD006007.pub2-BIB44|cit44","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336(7644)","author":"Wood","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006007.pub2-BIB45|cit45","unstructured":"Zavala D Mart\u00ed A Pe\u00f1a-Mart\u00ed G Comuni\u00e1n G Sheet to enter data for performing a Cochrane review 2006"},{"issue":"1","key":"10.1002\/14651858.CD006007.pub2-BIB46|cit46","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006007.pub2","article-title":"Antifibrinolytic amino acids for acquired coagulation disorders in patients with liver disease","author":"Marti-Carvajal","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006007.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:53:42Z","timestamp":1628546022000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006007.pub2"}},"subtitle":[],"editor":[{"given":"Arturo J","family":"Mart\u00ed-Carvajal","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2007,1,24]]},"references-count":46,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006007.pub2","relation":{},"subject":[],"published":{"date-parts":[[2007,1,24]]}}}